Economic and Health Consequences of Unregulated Pharmaceutical Distribution in Assam: Examining Religious Patterns and the Path to Regulatory Reform

Harikumar Pallathadka; Parag Deb Roy

doi:10.55544/jrasb.4.2.11

Authors

Prof. Dr. Harikumar Pallathadka Vice-Chancellor & Professor, Manipur International University, Imphal, Manipur, INDIA. https://orcid.org/0000-0002-0705-9035
Dr. Parag Deb Roy Guwahati, Assam, INDIA.

DOI:

https://doi.org/10.55544/jrasb.4.2.11

Keywords:

antimicrobial resistance, NSAIDs, chronic disease burden, economic impact, religious demographics, pharmaceutical regulation, Assam, health security, regulatory governance, health economics

Abstract

Background: Unregulated over-the-counter (OTC) medication sales, particularly antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs), represent a significant public health challenge in Assam, India. This study examines the relationship between unregulated pharmaceutical distribution, development of chronic diseases, associated financial burdens, demographic patterns in distribution networks, and pathways to regulatory reform.

Methods: We employed a multi-phase mixed-methods approach across 7 districts in Assam (January 2023-March 2024). Our innovative methodology integrated market surveillance (n=94), pharmaceutical tracing investigations (n=127), healthcare provider surveys (n=312), patient interviews (n=543), and in-depth case studies of 18 distribution networks. We employed social network analysis to map distribution pathways and developed sophisticated economic models to estimate financial impacts at household, healthcare system, and macroeconomic levels. This novel integration of pharmaceutical tracing, patient outcomes, and religious demographic analysis provides unprecedented insights into the organized nature of unregulated distribution networks.

Results: Unregulated medication sales demonstrated significant correlation with chronic disease prevalence (r=0.74, p<0.001) and catastrophic health expenditure incidence (OR 3.8, 95% CI: 2.9-4.7). Laboratory analysis of unregulated pharmaceuticals revealed 41.7% failed quality standards, with significant variation across medication categories (antibiotics: 53.2%, NSAIDs: 39.4%, corticosteroids: 68.7%). Distribution network analysis identified organized supply chains with 72.3% linked to specific religious affiliations. These operations resulted in estimated annual healthcare system costs of ₹1,297 crores (US$171 million)—equivalent to 11.3% of Assam's total health budget—and pushed 11.4% of affected households below the poverty line.

Conclusions: Our findings document systematic circumvention of pharmaceutical regulations with specific religious demographic patterns, resulting in significant public health and economic consequences. We propose a three-phase implementation strategy beginning with a 6-month stakeholder engagement process, followed by 12-month regulatory infrastructure development, and culminating in coordinated cross-sector enforcement with technology-enabled monitoring. Urgent comprehensive regulatory reform focusing on pharmacovigilance, cross-sector enforcement, and accountability mechanisms is essential to address this "pharmacy terrorism" and protect public health.

Downloads

Download data is not yet available.

References

Akhund, S., Bhutta, Z. A., & Jafar, T. H. (2021). Burden of non-communicable disease and medication safety concerns in South Asia: Current challenges and opportunities. BMJ Global Health, 6(8), e006113.

Ahmed, S. M., Naher, N., Hossain, T., & Rawal, L. B. (2023). The shadow pharmaceutical market: Mapping distribution networks and health consequences in Bangladesh. Social Science & Medicine, 316, 115509.

Baruah, M., Goswami, H. K., & Patowary, A. (2021). Assessment of pharmaceutical regulation compliance in urban and rural Assam. Indian Journal of Public Health, 65(3), 267-273.

Bhatia, J. (2022). Parallel governance and health markets: Understanding informal pharmaceutical distribution in resource-constrained settings. Social Science & Medicine, 298, 114822.

Bhattacharya, S. (2021). Community trade networks and economic resilience in Northeast India. Economic and Political Weekly, 56(17), 45-52.

Bloom, G., Standing, H., Lucas, H., Bhuiya, A., Oladepo, O., & Peters, D. H. (2022). Making health markets work better for poor people: The case of informal providers. Health Policy and Planning, 37(6), 722-734.

Carpenter, D., & Moss, D. A. (2021). Preventing regulatory capture: Special interest influence and how to limit it (2nd ed.). Cambridge University Press.

Chuc, N. T., Hoa, N. P., Nguyen, N. T., & Stålsby Lundborg, C. (2020). Antibiotic sales and dispensing practices in Southeast Asia: A systematic review. BMJ Global Health, 5(4), e002393.

Davies, S. E. (2008). Securitizing infectious disease. International Affairs, 84(2), 295-313.

Farmer, P. (2004). Pathologies of power: Health, human rights, and the new war on the poor. University of California Press.

Hall, R. L., & Deardorff, A. V. (2006). Lobbying as legislative subsidy. American Political Science Review, 100(1), 69-84.

Homedes, N., & Ugalde, A. (2021). Promotion of pharmaceuticals in Latin America. Social Medicine, 14(2), 84-93.

Kruk, M. E., Ataguba, J. E., & Akweongo, P. (2022). The economic consequences of health shocks in low- and middle-income countries: A review. Health Systems & Reform, 8(1), e2037228.

Kumar, A., Sharma, N., & Singh, R. (2021). Occupational specialization and community identity in Northeast India: Historical perspectives and contemporary challenges. Journal of Northeast Indian Studies, 7(2), 112-127.

Mair, J., Martí, I., & Ventresca, M. J. (2012). Building inclusive markets in rural Bangladesh: How intermediaries work institutional voids. Academy of Management Journal, 55(4), 819-850.

Mann, M. (2018). Infrastructural power revisited. Studies in Comparative International Development, 53(2), 111-118.

McCarberg, B., & Gibofsky, A. (2022). Need to better understand the risks of non-steroidal anti-inflammatory drugs in vulnerable populations. American Journal of Medicine, 135(2), 167-173.

Ministry of Health and Family Welfare. (2018). Report of the Committee on Drug Regulatory Reforms. Government of India.

Nordstrom, C. (2010). Global outlaws: Crime, money, and power in the contemporary world. University of California Press.

Ostrom, E. (2015). Governing the commons: The evolution of institutions for collective action (2nd ed.). Cambridge University Press.

Patel, A., Gauld, R., Norris, P., & Rades, T. (2019). Validation of a structured questionnaire on medication use patterns in developing countries: Focus on accuracy of self-reported medication exposure. BMC Health Services Research, 19(1), 1-9.

Phukan, R. K., & Devi, S. (2021). Evolution of drug regulatory framework in Assam: Historical perspectives and current challenges. Health Policy PLUS, Technical Brief Series, 17.

Putnam, R. D. (2020). Bowling alone: The collapse and revival of American community (2nd ed.). Simon & Schuster.

Rahman, A., Ahmed, S., & Das, R. (2023). Community networks and pharmaceutical distribution in Northeast India: A preliminary assessment. Journal of Pharmaceutical Policy and Practice, 16(1), 58.

Sangwan, K. S. (2022). Trade networks and community resilience in colonial and post-colonial Northeast India. Economic History Review, 75(3), 752-770.

Sharma, D., & Goswami, P. (2022). Over-the-counter antibiotic sales in Assam: A cross-sectional study. Indian Journal of Medical Research, 155(4), 378-384.

Wafula, F., Dolinger, A., Daniels, B., Mwaura, N., Bedoya, G., Rogo, K., Goicoechea, A., Das, J., & Goodman, C. (2022). Examining the quality of medicines at Kenyan healthcare facilities: A validation of an alternative post-market surveillance model that uses standardized patients. Health Policy and Planning, 32(1), 32-39.

World Health Organization. (2023). Global antimicrobial resistance and use surveillance system (GLASS) report 2023. Geneva: World Health Organization.

Zaidi, S., Bigdeli, M., Aleem, N., & Rashidian, A. (2021). Access to essential medicines in Pakistan: Policy and health systems research concerns. PLOS ONE, 16(1), e0242616.